Low Egg Yield or Few Mature Eggs in One Cycle: What to Review Before Treatment in Thailand

A cycle that produced few eggs, or few mature eggs, is disappointing, but it is also one of the most informative events in fertility care. One retrieval gives your clinicians a set of measurements they did not have before: how your ovaries responded to a particular protocol and dose, how many follicles developed, how many eggs were collected, how many of those were mature, and what happened afterwards.

The useful question before planning treatment in Thailand is therefore not “what went wrong?” but “what does this cycle tell us, and what would we change or test next?” This guide sets out how to organise that review so a consultation starts with evidence rather than starting from scratch.

First, separate two different problems

Patients often describe a low-yield cycle as “poor response”, but two distinct situations sit under that phrase, and they lead to different review questions.

• Poor ovarian response describes a cycle in which few follicles developed and few eggs were retrieved. The review focuses on ovarian reserve markers, the stimulation protocol and starting dose, how the dose was adjusted, and whether the trigger was timed well.
• Low mature-oocyte yield describes a cycle in which a reasonable number of eggs was retrieved, but a small proportion of them were mature. The review focuses on trigger type and timing, the interval between trigger and retrieval, and how maturity was assessed in the laboratory.

The two can occur together, and both can occur alongside poor fertilisation or poor embryo development. Before a consultation, write down which description fits your cycle, using the numbers in your report rather than your memory of how it felt. If you are unsure, bring both sets of numbers and let the clinician characterise the cycle.

The records that make a review possible

A Thai clinic reviewing a cycle performed elsewhere needs the raw data, not only a summary letter. Ask the treating clinic for a full cycle report and, where available, the laboratory record. The items below are the ones that most directly inform a discussion about stimulation and maturation strategy.

Record	Why it matters for the review
Stimulation protocol name, starting dose and any dose changes with dates	Shows what was already tried and how the ovaries responded to it
Ovarian reserve markers measured before the cycle (for example AMH and antral follicle count, if done)	Provides context for whether the response was expected
Follicle counts and sizes on trigger day	Links the number of developing follicles to the number of eggs retrieved
Estradiol trend across stimulation	Helps interpret follicular growth and the decision to trigger
Trigger medication, dose and exact time; retrieval time	Central to any question about maturation timing
Eggs retrieved, mature (MII) eggs, and maturation rate	Distinguishes a response problem from a maturation problem
Fertilisation method and results; embryo numbers and stages reached	Shows whether the difficulty continued after retrieval
Any genetic testing performed on embryos and its outcome	Relevant if testing was part of the previous plan

Two practical points. First, ask for records with dates and units, because dose and timing questions cannot be answered from a narrative summary. Second, keep your own plain-language timeline of the cycle — start of stimulation, trigger, retrieval, transfer or freeze — since clinics sometimes hold fragments of the file in different departments.

Questions worth putting to the clinician

These are clinical questions, and they belong with the treating doctor or a fertility specialist, not with a coordination service. A useful consultation covers them in roughly this order.

1. How would you characterise the last cycle? Was this a response issue, a maturation issue, both, or something else in the laboratory pathway?
2. What would you keep and what would you change? Ask specifically about protocol family and starting dose, and about whether a different trigger approach or trigger-to-retrieval interval would be considered.
3. How is maturity assessed in your laboratory? Maturity is judged from the appearance of the egg at collection; ask how that assessment is done and recorded.
4. Is a repeat cycle with adjustment reasonable, or is a different strategy worth discussing? This may include further investigation before another stimulation, or a conversation about what is realistic given your history.
5. What would you want to see in the next cycle to judge whether the change worked? Agreeing in advance what counts as progress prevents another cycle being judged only by its final outcome.
6. What can and cannot be predicted? No clinician can promise a specific egg number, maturity rate, embryo count or pregnancy outcome before assessment, and any plan should be described in terms of possibilities rather than guarantees.

If embryo testing is part of the discussion, keep the purpose clear. PGT-A examines chromosome number in cells sampled from an embryo; it has limitations and can produce incorrect findings, and whether to use it should be discussed for the individual situation rather than assumed. A PGT-A result does not guarantee a successful pregnancy or a healthy child (HFEA). Where a reported finding is intermediate or mosaic, that is a sample-based inference rather than a description of the whole embryo, and technical factors can contribute to it (ASRM). PGT-M and PGT-SR address different questions again — a known monogenic condition and a chromosomal structural rearrangement respectively — and suitability is a matter for the treating team and a genetic counsellor (HFEA).

What a low-yield cycle does not tell you

It is tempting to read a single cycle as a fixed prognosis. It is better read as one observation under one set of conditions. A protocol change, a different trigger decision or a different starting dose may produce a different picture — or may not. What cannot be promised before a clinician reviews your records is any particular egg count, maturation rate, embryo number or chance of pregnancy.

This is also why comparing clinics by headline figures is a weak substitute for a case review. If you do want to research provider options, treat any shortlist as a starting point for questions about how a clinic would approach your specific history, not as evidence about your likely outcome. A countrywide overview of IVF hospital and clinic options in Thailand can help you organise that research.

Planning the practical side from abroad

Once the clinical questions are clear, the logistics become manageable. Three areas usually need attention before travel.

Getting a useful remote consultation

Ask what format the consultation takes, which records the clinic wants in advance and in what language, whether there is a fee, and who will review the file before the appointment. Sending records ahead is what makes a first conversation substantive rather than introductory. If you use a coordination service, its role is to organise records and relay questions and appointment arrangements; interpretation of results and any treatment recommendation remain with the clinicians.

Timing and travel dependencies

Stimulation and retrieval are tied to your cycle dates, so travel planning depends on a schedule the clinic confirms. Before booking anything, clarify the expected length of stay, which appointments must be in person, and what happens if dates shift. General guidance on planning an IVF timeline in Thailand can help you map those dependencies, and a review of stimulation protocol options will make the protocol conversation easier to follow.

Records to bring home

Whatever the outcome, ask before you leave how you will receive the cycle record, who will send it, and in what format. A complete record of the next cycle is what makes the following review possible — and if you are considering further treatment elsewhere, it is the document that travels with you.

A worked example of the review

Consider a hypothetical patient whose report shows a standard antagonist protocol, nine follicles above 14 mm on trigger day, seven eggs retrieved, two mature, one fertilised, no blastocyst. Her review has two layers. The retrieval-to-follicle ratio suggests the response itself was not the main issue; the low mature count and the drop-off afterwards are where the questions concentrate. She would ask about trigger timing and type, how maturity was assessed, and whether anything in the laboratory pathway explains the fertilisation result. She would also ask what the team would monitor differently next time. She would not ask a coordinator to interpret the numbers, and she would not expect a promise of a better result.

That is the shape of a good pre-treatment review: specific records, specific questions, and a clear line between what the clinician decides and what you can prepare.

Frequently asked questions

Can a clinic in Thailand tell me in advance how many eggs I will produce next cycle?

No. Egg numbers depend on your response to a specific protocol and cannot be guaranteed before assessment. A clinician can review your previous cycle records, explain what they would adjust and what they would monitor, and describe possibilities rather than promise a count.

Should I repeat the same protocol if the first cycle produced few eggs?

That is a clinical decision for the treating specialist after reviewing your protocol, doses, trigger timing and laboratory results. Some histories support adjusting the existing approach; others prompt a different discussion. Bring the full record so the decision is based on data rather than on the outcome alone.